ApoPharma's Ferriprox Gamble Pays Off In Panel Vote, But What About FDA?
Executive Summary
ApoPharma's risky move in not complying with FDA's request for an additional randomized controlled trial of its iron overload treatment Ferriprox (deferiprone) paid off in a lopsided advisory panel vote in favor of approval, but the agency has yet to give the final word.
You may also be interested in...
ApoPharma's Ferriprox Clears ODAC Based In Part On Dosing Convenience
Approved thalassemia treatments are "onerous" compared to Ferriprox, which has been marketed in Europe for 12 years.
ApoPharma's Preemptive Safety Strategy For Ferriprox Includes Centralized Pharmacy Distribution
ODAC will consider Ferriprox (deferiprone) as second-line treatment for transfusional iron overload; the company hopes for an endorsement of its patient and provider registries as well.
Ferraprox Advisory Cmte: Can Risk Management Overcome Safety, Dosing Worries?
ApoPharma's transfusional iron overload treatment has been approved in Europe since 1999, but FDA sent a "complete response" letter in 2009.